VaxInnate Inc.
This article was originally published in Start Up
Executive Summary
VaxInnate is linking the innate and adaptive immune response to get the optimal action from a vaccine. Work done in the Yale labs of company founders demonstrated that fusing a polypeptide ligand specific for a TLR to an antigen of interest generates a vaccine that may prove more potent and selective than the antigen alone. It also eliminates the need for formulating the vaccine in complex adjuvants-and it opens the door to production using simplified recombinant methods.